PANCREATIC CANCER

This early-phase study tests a new type of radiation therapy called SCART for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the highest safe dose that can be given to the tumor while protecting nearby organs. About 24 adults…

This phase 3 study tests a new drug, daraxonrasib, against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug or standard thera…

This study tests a combination of targeted radiation (SBRT) and a chemotherapy cocktail (NALIRIFOX) in 42 people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth and improve survival. Participan…

This study gave one patient with pancreatic cancer stem cells taken from a family member's fat. The goal was to help control the cancer and ease symptoms like pain and fatigue. The treatment was only available to people who were stable enough to receive it.

This study offers ongoing treatment with ruxolitinib (alone or with other cancer therapy) to people with pancreatic, colorectal, breast, or lung cancer who were already benefiting from it in a previous Incyte study. It includes up to 10 participants and focuses on tracking side e…

This study tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The goal is to see if this gentler radiation, given with the chemotherapy drug gemcitabine, causes fewer side effects than standard rad…

This study looks at how safe and effective glipizide, a standard diabetes drug, is for lowering blood sugar in people with pancreatic cancer. About 29 adults with active pancreatic cancer and high blood sugar will take glipizide and have their glucose levels monitored. The goal i…

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy before surgery is safe and doable for people with pancreatic cancer that can be removed. About 20 adults with early-stage disease will receive the combination treatment. The main goal is t…

This study tests whether adding the experimental drug ZN-c3 to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer live longer without their disease getting worse. It involves 12 participants whose cancer has returned or not responded to prior plat…

This early-phase study tests whether a personalized cancer vaccine, combined with an immunotherapy drug (atezolizumab) and chemotherapy, is safe for people with pancreatic cancer that has been surgically removed. About 29 participants will receive the vaccine, which is custom-mad…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help control the cancer. About 350 people with various cancer types, …

This study tests whether a higher-than-standard dose of radiation, given with chemotherapy, can shrink pancreatic tumors enough to allow surgery. It involves 47 adults with locally advanced pancreatic cancer that cannot be removed initially. The goal is to see if this approach he…

This study tests a new combination of two experimental drugs (AGEN1423 and botensilimab), with or without standard chemotherapy, in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors…

This phase 3 trial tests whether giving chemotherapy both before and after surgery helps people with pancreatic cancer live longer compared to chemotherapy only after surgery. About 378 patients with resectable pancreatic cancer will be randomly assigned to one of two treatment s…

This study tests whether giving chemotherapy both before and after surgery (perioperative) works better than only after surgery (adjuvant) for people with pancreatic cancer that can be removed. About 358 participants will receive a combination of common chemo drugs. The goal is t…

This study tests whether adding a new immunotherapy combination (aldoxorubicin, N-803, and PD-L1 t-haNK) to standard chemotherapy helps people with advanced pancreatic cancer live longer without their disease getting worse. About 328 adults with cancer that has spread or cannot b…

This study tests whether adding the experimental drug Ampligen to standard treatment can help people with locally advanced pancreatic cancer live longer without their disease getting worse. About 90 adults who have already completed at least four months of first-line therapy with…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests a new drug called NUV-1511 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors. The study includes people with certain breast, prostate, pancreatic, and ovarian can…

This early-phase trial tests a new drug (TTI-101) combined with targeted radiation for people with pancreatic cancer that cannot be removed by surgery right away. The goal is to see if the combination is safe and can help keep the cancer from growing for longer. About 5 participa…

This study compares two ways to unblock the bile duct in people with cancer that is blocking it. One method uses an ultrasound-guided stent, the other is a standard scope procedure. The goal is to see which method fails less often and causes fewer cases of pancreatitis. About 120…

This study tests whether adding zolbetuximab (a drug that targets a protein called CLDN18.2 found in many pancreatic tumors) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 393 adults whose cancer has spread and has the CLDN18.2 marker w…

This early-stage trial tests a combination of two experimental drugs, defactinib and VS-6766, in people with advanced solid tumors that have not responded to standard treatments. The study includes patients with certain lung, ovarian, endometrial, or pancreatic cancers. The main …

This study tests a new drug called TST001, an antibody that targets a protein (CLDN18.2) found on some cancer cells. It is for people with advanced solid tumors, including stomach, gastroesophageal junction, and pancreatic cancers. The trial aims to find safe doses and see how we…

This phase 2 study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can help control colorectal and pancreatic cancers that are either microsatellite stable or MSI-high. About 84 adults with these cancers will receive the treatment…

This early-stage study tests an experimental pill called HBI-2376 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific gene changes (KRAS or EGFR mutations). The main goals are to find the safest dose and understand how the drug moves t…

This study tests a new device that places tiny alpha radiation seeds directly into pancreatic tumors. It includes 37 adults with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the procedure is safe and possible, and to check early signs of tum…

This study tests whether adding an experimental drug called PEGPH20 to standard chemotherapy can shrink advanced pancreatic tumors. PEGPH20 breaks down a substance called hyaluronan, which is often found in high amounts in these tumors and may help them grow. The study involves 1…

This study tests a treatment plan for people with pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery to remove the tumor and the affected artery. The goal is to see if this aggressive approach is safe and helps pati…

This study tests a new drug called ABTL0812 added to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has spread. The goal is to see if the combination is safe and works better than chemo alone. About 60 adults with newly diag…

This study tested a two-step treatment for people with pancreatic cancer that is either borderline removable or locally advanced but hasn't spread. First, patients received a strong chemotherapy combination called modified FOLFIRINOX, followed by precise, high-dose radiation (SBR…

This study tests whether adding losartan (a blood pressure drug) and nivolumab (an immunotherapy) to standard chemotherapy and radiation can improve surgical outcomes for people with localized pancreatic cancer. About 168 participants with borderline resectable or locally advance…

This study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. It involves 3 adults with newly diagnosed advanced or metastatic pancreatic cancer. The goal is to see if…

This study tests the safety and effectiveness of combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) in people with metastatic pancreatic cancer that has spread to other parts of the body. The goal is to see if this combination can help control the disea…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…

This early-phase study tests a vaccine targeting mutant KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in patients with colorectal or pancreatic cancer that has been surgically removed. The goal is to see if the combination is safe and boosts the…

This study is testing different combinations of immunotherapy drugs given before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if these treatments can boost the immune system to fight the cancer better. About 76 participants will be e…

This early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, es…

This study planned to see if giving extra chemotherapy after surgery could help people with pancreatic cancer live longer without the disease coming back. It was designed for patients who had already received chemotherapy before surgery. However, the study was withdrawn before an…

This study tests whether adding a drug called ATRA (a form of vitamin A) to standard chemotherapy can help people with locally advanced pancreatic cancer live longer without their disease getting worse. About 170 participants will receive either chemo alone or chemo plus ATRA. Th…

This study tests a combination of two drugs, atezolizumab and cabozantinib, in 30 people with advanced pancreatic cancer that has stopped responding to standard treatments. The goal is to see if the combo can shrink tumors or slow the disease. Researchers will also monitor side e…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This study is testing an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The goal is to see if the drug is safe and tolerable when given alone or with other cancer treatments. About 70…

This study tests a new combination of drugs (futibatinib plus a PD-1 antibody) in adults with advanced esophageal or pancreatic cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and is safe. About 53 people will take part, and they must not …

This early-phase study tests a new combination of treatments for people with pancreatic cancer that has not responded to standard therapies. The approach combines two immunotherapy drugs (nivolumab and ipilimumab) with a vaccine targeting a protein called TGFβ-15 and precise radi…

This early-phase study tests a combination of two drugs (palbociclib and gedatolisib) in people with advanced lung, pancreatic, head & neck, or other solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can slow can…

This study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has not spread through families. Participants have already completed at least 4 months of standard chemotherapy and their disease is stable. The drug is given weekly through an IV in 4-week…

This study tests whether adding surufatinib to standard chemotherapy can help shrink pancreatic tumors enough for successful surgery. It includes 29 adults with locally advanced or borderline resectable pancreatic cancer who have not had prior treatment. The main goal is to see h…

This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is …

This study looks at side effects of a 3-week radiation and chemotherapy treatment for people with pancreatic cancer that hasn't spread. It includes 103 adults with different stages of the disease. Researchers will also take blood samples to measure cancer DNA levels and see how t…

This early-phase study tests whether adding two immune-boosting drugs (canakinumab and tislelizumab) to standard chemotherapy can safely shrink pancreatic tumors before surgery. Nine adults with resectable or borderline resectable pancreatic cancer will receive the combination. T…

This study aimed to see if a person's own immune cells, modified in a lab to target specific cancer gene mutations, could prevent gastrointestinal cancers from coming back after standard treatment. It was designed for people with certain gene changes and blood markers suggesting …

This study was designed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides more accurate diagnosis of cancer. However, the study was withdrawn before any participants were e…

This pilot study tests a special PET scan that uses a radioactive tracer (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with breast, colon, lung, or other CEA-positi…

This study was designed to test a new type of PET scan that uses two special substances to find cancer cells with a marker called CA19-9. It was planned for people with pancreatic, bladder, or gastrointestinal cancers. However, the study was withdrawn before any participants were…

This study was designed to check if a new blood test can find hidden pancreatic cancer in people aged 50 and older who were recently diagnosed with type 2 diabetes. The test looks for cancer signals, and if positive, participants would get an MRI to confirm. The goal was to catch…

This study tests whether taking pancreatic enzyme pills (pancrelipase) can help people with metastatic pancreatic cancer maintain or gain weight. The study includes 17 participants who are starting chemotherapy. Researchers will compare two different dosing schedules and measure …

This study tests whether using a FitBit and mobile health apps can help people who have had surgery for cancers of the stomach, liver, pancreas, colon, or small intestine avoid being readmitted to the hospital. About 107 adults who own a smartphone and are scheduled for surgery w…

This study looks at whether regular exercise and behavioral skills training can improve physical fitness and quality of life in people with pancreatic cancer who are getting chemotherapy or radiation before surgery. About 128 participants will take part at MD Anderson. The main g…

This study tests a program that lets cancer patients receive care at home while undergoing chemotherapy or radiation. The goal is to see if remote monitoring and home support can reduce emergency room visits and hospital stays. About 300 adults with certain cancers (like pancreat…

This study looks at whether starting palliative care early can improve quality of life and possibly survival for people with advanced pancreatic cancer. About 250 adults with incurable pancreatic cancer will receive specialized palliative care soon after diagnosis. The goal is to…

This study tests whether a supervised video-based exercise program, done during chemotherapy before surgery, can help people with pancreatic cancer feel better and have fewer complications. About 58 patients will take part. The goal is to see if the program is safe and improves r…

This study tests a program that gives pancreatic cancer patients extra nutrition support from dietitians through remote visits and a fitness tracker. The goal is to see if patients find the program helpful and easy to use while on chemotherapy. About 80 adults with advanced pancr…

This early-phase study tests whether ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) similar to ibuprofen, is safe and can help stabilize or increase weight in people with advanced pancreatic cancer who are experiencing cachexia (unintended weight loss). About 28 partici…

This study looks at whether a new imaging analysis method, called radiomics, can help doctors identify which patients with advanced pancreatic cancer are not responding to chemotherapy early on. Researchers will analyze scans from 400 adults to see if tumor changes can predict su…

This study looks at 271 people with pancreatic cancer to find genetic mutations that might increase risk. Researchers will collect personal and family health history to build a tool that helps identify who is at higher risk. Participants also get genetic counseling and are asked …

This study looks at a protein called DCAMKL-1, which may be a stem cell marker in pancreatic cancer. Researchers want to see how levels of this marker change before and after treatment in 60 people with pancreatic cancer. The goal is to better understand how current therapies aff…

This study is creating a detailed registry of pancreatic cancer patients in Korea, combining past records from 2010 to 2022 with new data collected through 2029. Over 6,900 participants will contribute information to help researchers understand the disease better and develop real…

This study collects blood, tissue, and medical images from 500 people with or suspected of having pancreatic cancer to create a biobank. The goal is to understand why outcomes differ among racial groups and to personalize treatment. Participants donate samples and complete questi…

This early-phase study tests whether a special PET scan tracer called 18F-FAC can measure how much of the standard chemotherapy drug gemcitabine is taken up by pancreatic tumors. About 30 adults with pancreatic ductal adenocarcinoma will receive a PET scan before starting treatme…

This study follows about 400 adults who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The main goal is to track long-term safety and see how well the treatment effects last over time. Participants do not receive ne…

This study looks at whether a remote nutrition coaching program is practical and well-liked by people with pancreatic cancer who are getting chemotherapy. The program lasts 12 weeks and aims to help patients manage their nutrition during treatment. The study involves 40 adults an…

This study tests whether a small monitoring probe placed near the surgical site can detect internal leaks early after pancreatic cancer surgery. About 200 adults having this operation will be randomly assigned to receive the probe or standard care. The goal is to see if early det…

This study collects leftover tissue, blood, and other body fluids from up to 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in future lab studies to learn more about what causes these cancers…

This study tests a program called IGNITE-TX that uses a website and a genetic family navigator to help relatives of people with hereditary cancer get free genetic counseling and testing. It involves 205 adults who have a known cancer gene mutation and their at-risk family members…

This study collects leftover tissue and blood samples from people with known or suspected cancer who are already scheduled for surgery or biopsy. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. No extra procedures are d…

This study tests a new computer tool that uses CT scans to predict how blood flow will change during major pancreatic surgery. The goal is to avoid the need for invasive angiography, which carries risks like radiation and vessel injury. About 100 adults scheduled for pancreatic s…

This study aims to create a test that uses circulating tumor cells to predict which chemotherapy regimen will work best for each person with advanced pancreatic cancer. Researchers will analyze tumor cells from 74 participants to see if the test can accurately forecast treatment …

This study explores whether a narrowed celiac artery (celiac axis stenosis) leads to more complications after pancreaticoduodenectomy, a major surgery for pancreatic cancer. Researchers followed 99 adults who had the surgery to track their recovery. The goal is to better understa…